Gastrointestinal symptoms are commonly reported in as much as 65% of people with CF even independent of pancreatic enzyme replacement therapy (PERT) and the most frequent of these symptoms are bloating/distension, flatulence, abdominal pain and bowel habit changes. An alteration in the intestinal microbiome due to intestinal dysmotility, inflammation or other changes including pH changes in the intestine related to CFTR gene mutation may cause intestinal dysbiosis leading to a bacterial overgrowth in the proximal small intestine which may explain some of the findings of distension and bloating in CF.
Our small pilot study aims to investigate use of the only FDA-approved antibiotic, rifaximin for a GI syndrome- IBS, to treat bloating and global GI symptoms in CF patients with bloating and distension. Our goal is to recruit patients >12 years and age/sex matched into rifaximin and placebo arms with total of 100 recruited subjects recruited.

开始日期2025-07-01

申办/合作机构

Wake Forest School of Medicine

[+3]

CTRI/2025/04/085492

/ Not yet recruitingN/AIIT

Comparative evaluation of rifaximin and lactulose in combination vs lactulose alone in prevention of constipation in critically ill chronic kidney disease patients; a randomized controlled trial. - nil

开始日期2025-05-03

申办/合作机构

All India Institute of Medical Sciences

NCT06483737

/ Not yet recruitingN/AIIT

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial

Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.

开始日期2025-05-01

申办/合作机构

中国人民解放军北部战区总医院

100 项与利福昔明相关的临床结果

登录后查看更多信息

100 项与利福昔明相关的转化医学

登录后查看更多信息

100 项与利福昔明相关的专利（医药）

登录后查看更多信息

1,719

项与利福昔明相关的文献（医药）

2025-12-01·Current Neurology and Neuroscience Reports

Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management

Review

作者: Chakravarty, Ambar ; Pan, Kausik ; Sen, Barun Kumar

PURPOSE OF REVIEW:

This review highlights the causes, types and clinical staging of hepatic encephalopathy (HE). Current concepts on the probable pathogenetic mechanisms and currently practiced therapeutic options are discussed.

RECENT FINDINGS:

HE may be covert and overt. Also known as minimal HE. Covert HE, where there are behavioral abnormalities and impairment in activities of daily living with intact sensorium. The pathophysiology of HE remains poorly understood. There is disturbance of the urea cycle due to liver disease leading to increased production of ammonia. The ammonium ion enters the astrocytes along with glutamate (converted to glutamine by ammonia) and myo-inositol, thereby increasing the osmolality of the astrocytic cytoplasm. This osmotic gradient results in accumulation of water inside the astrocytes resulting in cerebral edema and increase in brain volume. Additionally, current research has noted the role of cerebral oxidative/nitrosative stress and the synergistic effects of increased cerebral ammonia and alteration in neurotransmitters, neurometabolites, and cortical excitability due to systemic inflammation. In advanced liver disease with systemic infection or inflammation, neuroinflammatory processes play significant role in the development of HE. Inflammatory cytokines like TNF-α, IL-6, IL-17 in presence of hyperammonemia have been found to induce neurotoxicity of ammonia by passing through the blood brain barrier and causing enlarged/swollen pale astrocytes, resulting in HE. Disrupted enterohepatic circulation in end stage liver disease also causes elevation of bile acids which induces neuroinflammation. Manganese and zinc play as co-factors of enzymatic reaction. These metal deposition causes multiple psychomotor symptoms observed in HE. The gut environment has a major impact on brain function in patients with HE. Toxins such as ammonia and inflammatory cytokines produced by this impaired intestinal flora access the circulation through porto-systemic anastomoses and exacerbate or precipitate HE. Finally, as a result of recurrent cerebral edema from astrocytic dysfunction and neuroinflammation, permanent neurodegeneration occurs with cognitive decline and motor disturbances, especially parkinsonian features and gait disturbances. This is the stage of chronic hepatic encephalopathy. Currently L-ornithine L-aspartate (LOLA) is being used to lower the ammonia level by stimulating the urea cycle. HE comprises a broad spectrum of neurological and/or psychiatric abnormalities caused by hepatic insufficiency and/or portal-systemic shunting in the absence of any other causes of brain dysfunction. HE may be caused or precipitated by several factors like infections, intoxications and drugs. The encephalopathic features may be covert or overt. The pathogenetic mechanisms for HE may be different. In the presence of liver disease, HE primarily results from disturbed urea cycle with hyperammonemia causing astrocytic swelling and cerebral edema. Porto-systemic anastomoses with intact liver function can cause HE by allowing ammonia and other toxins produced by the gut microbial flora and allowing these to bypass detoxification by the liver and exposing the brain to their harmful effects. Principles of therapy are twofold. First protecting the liver and the brain from gut generated ammonia and other toxins by ensuring smooth bowel function and avoiding stagnation with the use of osmotic laxatives like lactulose or lactitol and also reducing the gut microbial load with use of anti-bacterials/bacteriophages like neomycin and rifaximin along with metronidazole. Second, reducing the already generated cerebral edema by use of mannitol and appropriate ventilatory support. Currently L-ornithine L-aspartate (LOLA) is being used to reduce the ammonia load to the liver. LOLA is a stable compound formed from two amino acids. L-ornithine plays a crucial role in stimulating the urea cycle, leading to a reduction in ammonia levels. Both L-ornithine and L-aspartate serve as substrates for the enzyme glutamate transaminase, and their administration results in elevated glutamate concentrations. Ammonia is subsequently utilized in the conversion of glutamate to glutamine through the action of glutamine synthetase. Finally in resistant cases the use of liver transplant needs to be considered. Alternatively extracorporeal liver assist devices may be used like Molecular Adsorbent Recirculating System (MARS) or Single-Pass Albumin Dialysis (SPAD).

2025-05-01·PHARMACOLOGICAL RESEARCH

DIORS: Enhancing drug-target interaction prediction via structure and signature integrated-driven approach and discovering potential targeted molecules

Article

作者: Hu, Wanting ; Jiang, Xuyong ; Han, Lu ; Zhao, Xueru ; Luo, Dan ; Xiao, Zhiyong ; Tang, Yiran ; Gao, Shengqiao ; Zhou, Wenxia ; Zhang, Yongxiang

Drug-target interaction prediction is critical for drug development. Through the integration of structural and transcriptional signature information, molecules both binding to the target and producing therapeutic activities could be found out to improve targeted drug prediction. Therefore, the approaches that integrate the two types of data are worth exploring. Here, we present an integrated method named Data Integration Oriented Repurposing Strategy (DIORS) combining molecular docking and gene-signature matching to enhance the prediction of protein-targeted drugs. The StandardScaler algorithm was selected after evaluation of five algorithms and was used in DIORS. Surface Plasmon Resonance (SPR) was used to verify the molecular affinities and cell-based assays were used to verify the activities of DIORS predicted molecules. In Piezo1-targeted molecule prediction, among the top ten predicted molecules by DIORS, four of them, namely gefitinib, rifaximin, bosutinib and vandetanib, exhibited binding affinities. In the prediction of TLR4/MD2-targeted anti-inflammatory molecules, among the top ten predicted molecules, three of them, namely enoxolone, dabrafenib and ponatinib, exhibit both high binding affinities and anti-inflammatory activities. The results demonstrated that DIORS can serve as a better approach with high performance to predict and find new targeted drugs by combining structural and signature information.

2025-05-01·EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Prior overt hepatic encephalopathy and hyponatremia are more strongly linked to recent driving accidents than measures of minimal hepatic encephalopathy

Article

作者: Chakraborty, Shardhya ; Sonthalia, Nikhil ; Goenka, Mahesh K. ; Ghoshal, Uday Chand ; Bhattad, Utkarsh ; Tewari, Awanish ; Ranjan, Vivek ; Roy, Akash

Background:

Cognitive impairment in cirrhosis is driven by multiple influencers. Those with cognitive impairment have greater traffic accidents and violations. While the presence of minimal hepatic encephalopathy has been associated with poor driving skills, studies show conflicting results and variable associations with regard to accidents.

Methods:

In a prospective study of stable outpatients with cirrhosis without a recent history of overt hepatic encephalopathy (OHE) (<3 months), we assessed, the overall practice of driving, recent (<1 month) self-reported accidents, and factors associated with driving accidents.

Results:

Of 433 patients, 147 (33.9%) [age, 55 (46–61) years, 97.9% males, 29.9% alcohol-related, 13.6% prior OHE, MELD 11 (10–16), lactulose use 45.5%, rifaximin use 23.1%] reported recent driving (≤1 month), of whom 22 (14.9%) had recent driving accidents. Those with reported accidents had a higher history of prior OHE (31.8 vs. 10.5%, P < 0.05) and lower sodium [131 (129–134) vs. 134 (132–138), P < 0.05]. Psychometric hepatic encephalopathy score (PHES) [−5.5 (−4 to −9), vs. −4 (−3 to −7), P = 0.10], alcohol as an etiology (22.7 vs. 31.2%, P = 0.68), MELD [12.5 (10–17) vs. 11 (9.7–16), P = 0.36], animal naming test [18 (16–23) vs. 18 (15–22), P = 0.35], outpatient fasting ammonia [93 (63.7–121.5) vs. 81 (67.2–96.2), P = 0.43] were similar. On univariate analysis, prior OHE, sodium levels and PHES [odds ratio (OR): 0.87 (0.75–1.0), P = 0.09], and animal naming test [OR: 0.89 (0.76–1.04), P = 0.10)] showed a trend of association, while on multivariable analysis only prior OHE [adjusted OR: 3.48 (1.07–10.74), P = 0.03] and sodium levels [adjusted OR: 0.89 (0.79–0.99), P = 0.03] were associated with recent driving accidents [model AUC (prior OHE + Na≤130), 0.70 (0.62–0.77)].

Conclusion:

In stable outpatients with cirrhosis, a remote history of OHE and hyponatremia are most strongly associated with recent driving accidents.

101

项与利福昔明相关的新闻（医药）

2025-05-07

·GlobeNewswire-Health Care

Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL

Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006)Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrenceIn vivo demonstration of ammonia scavenger mechanism of action highlights potential synergistic combination with TLR-4 antagonist (YAQ005) LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, is this week revealing data on the progress of both its phase 3 and phase 2b/3 candidate drugs – YAQ006 (IV) and YAQ007 (oral) - for hepatic encephalopathy (HE) at the forthcoming European Association for the Study of the Liver (EASL) Congress, Amsterdam May 7-10th in advance of its clinical trials. Collectively, the data provide an enhanced understanding of the mechanism of action, determine treatment-initiation and endpoints within the HE patient population and define the dosage of YAQ007 (the oral formulation of the ammonia scavenger) to be used for the prevention of recurrence of overt HE. “EASL 2025 represents a great opportunity for Yaqrit to share data with clinicians and researchers in the liver disease community as we approach late-stage clinical investigation of YAQ006 and YAQ007,” said Troels Jordansen, Yaqrit’s Chief Executive Officer. “There are clear unmet medical needs in advanced liver disease: the EASL presentations demonstrate that Yaqrit is on course to put the right drug in the right patients at the right time and at the right dosage.” YAQ006 and YAQ007 are, respectively, the intravenous and oral formulations of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a phase 3 trial with YAQ006 for hospital treatment of overt HE, a life-threatening complication of decompensated cirrhosis and a phase 2b/3 trial with YAQ007 for outpatient use to prevent recurrence of overt HE. One key disclosure at EASL is the development of a patient-staging protocol – mHEST (modified Hepatic Encephalopathy Staging Tool). Use of mHEST has been approved by the US Food and Drug Administration (FDA) to evaluate the primary endpoint of ‘clinically meaningful improvement’ for the phase 3 trial of YAQ006 in patients with overt HE. The strong levels of inter- and intra-rater concordance within mHEST will reduce dependence on subjective assessment and interpretation, helping clinical investigators at various centers make consistent choices in patient selection and endpoint attainment across the trial. Development and validation of the modified hepatic encephalopathy staging tool (mHEST) for grading of hepatic encephalopathy for accurate assessment and regulated clinical trials (SAT-210). Prof. Rajiv Jalan, Saturday 10th May. The dose-setting clinical study for YAQ007 (oral formulation of L-OPA) is described in a second EASL presentation. Patients who received 4 g of YAQ007 twice daily showed a decrease in plasma ammonia that was 6 times the decrease seen with rifaximin (550mg twice daily), an antibiotic used in the current standard treatment for hepatic encephalopathy. There was no significant difference in adverse events. Randomized, open-label, phase 2a comparator study to assess the pharmacodynamics, safety and pharmacokinetics of oral administration of mnk6106 (l-ornithine phenylacetate) vs. rifaximin in subjects with hepatic cirrhosis and a previous history of hepatic encephalopathy (SAT-209). Prof. Rajiv Jalan, Saturday 10th May. Transcription and metabolic analysis in mouse models of HE provides evidence that the mode of action of L-OPA may be complementary to that of YAQ005, a TLR4 antagonist, in treating hyperammonemia. This raises the possibility of improved therapeutic strategies in the future. Transcriptomic and metabolic insights into hyperammonemia: the complementary therapeutic roles of toll-like receptor 4 inhibitor and ornithine phenylacetate (THU-182). Dr. Supachaya Sriphoosanaphan, Thursday 8th May. “In treating and preventing advanced liver disease with multiple complicating factors in play, there is no substitute for understanding, whether in controlling clinical trial variables or understanding mechanisms of drug action,” said Professor Rajiv Jalan, Yaqrit’s Founder and Chief Medical Officer. “These impressive data underpin confidence in the clinical pathway for Yaqrit’s pipeline assets.” Information on Yaqrit’s eight presentations at EASL 2025 can be found on Yaqrit’s website under latest news. The full abstracts will be available on the EASL Congress website from 08:30AM CEST on 7th May 2025. Contact Company Troels Jordansen Email: Troels@Yaqrit.com Tel: +31 6 1834 5326 Contact Investors Mary-Ann Chang Email: Mary-Ann@Yaqrit.com Tel: +44 7483 284 853 About Yaqrit Yaqrit is a clinical-stage company discovering and developing innovative treatments for patients with advanced liver disease at high risk of hospitalization and death. Yaqrit’s pipeline includes three novel therapeutics at phase 2-3 of development and two medical devices providing acute and chronic treatments for advanced cirrhosis and acute-on-chronic liver failure where there is an urgent need for more effective treatments. More information is available at www.Yaqrit.com About Hepatic Encephalopathy Hepatic encephalopathy (HE) is a potentially reversible neurological dysfunction associated with excess ammonia in the blood. As many as 40% of decompensated cirrhosis patients are at risk of developing hepatic encephalopathy, with over 80,000 patients hospitalized in the US every year with overt episodes. The recurrence of hepatic encephalopathy is high: a second episode will follow the initial overt event within a year in 40-50% of patients.

临床结果临床3期临床2期

2025-05-06

·ir.bauschhealth.com

Xifaxan® (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

May 06, 2025 New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, Quebec, May 6, 2025 – Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had a reduced risk of OHE-related rehospitalization within 30 days if treated with Xifaxan® (rifaximin) following hospital discharge regardless of prior treatment. These findings, based on a claims-based analysis, will be presented today at Digestive Disease Week® (DDW) 2025 in San Diego, CA. “This analysis reinforces the use of Xifaxan to help prevent OHE rehospitalizations,” said Arun Jesudian, MD, Director of Inpatient Liver Services at NYPH/Weill Cornell. “Cases of chronic liver disease and cirrhosis are growing, and these conditions can be debilitating for patients and their families. Providing patients with optimal, guideline-based treatment regimens is imperative because preventing recurrence and rehospitalizations not only benefits patients but also helps reduce burden on the broader healthcare system.” In patients with cirrhosis, an occurrence of fully symptomatic overt hepatic encephalopathy (OHE) is one of the key complications that defines the decompensated phase of the disease and is associated with worsening outcomes, morbidity, and mortality.1 Because in cirrhosis a damaged liver does not function normally, toxins from the gut can enter the bloodstream and travel to the brain, where they can affect neurotransmission precipitating OHE episodes. These episodes may present as alterations in consciousness, cognition, and behavior.2,3 Up to 80% of patients with cirrhosis will eventually develop some form of HE.1 American Association for the Study of Liver Diseases (AASLD) treatment guidelines recommend the use of Xifaxan as an add-on treatment to lactulose after a breakthrough OHE episode to prevent further OHE recurrence.1 Results of this claims-based analysis showed that patients who received lactulose only upon hospital discharge had a higher risk of 30-day OHE rehospitalization compared to those who received Xifaxan (adjusted OR: 1.63-2.73, p<0.05) regardless of pre-hospitalization treatment. Additionally, the risk of 30-day OHE rehospitalization increased with descending tiers of quality of care (QoC), defined as high-, intermediate- or low-quality based on AASLD guidelines (intermediate vs. high QoC: OR = 1.44, low vs. high QoC: OR = 2.45, all p<0.05). Results remained consistent for Medicare- and Medicaid-insured patients. “Xifaxan has been proven to effectively reduce the risk of OHE recurrence, so it is concerning to know that some patients leave the hospital without guideline-based treatment recommendations,” said Aimee Lenar, Executive Vice President of US Pharma at Bausch Health. “It is vital to recognize hepatic encephalopathy in people with liver disease in the hospital setting and to ensure they have access to high-quality, holistic care upon discharge.” The analysis used claims data from the Komodo Research Data (January 2016 – September 2023) to identify commercially-insured patients with an initial OHE hospitalization. Of the 7,880 OHE patient claims data analyzed, prior to hospitalization, 27.1 percent (n=2,135) were treated with Xifaxan, 24.1 percent with lactulose and 48.8% (n=3,848) received no treatment. About XIFAXAN INDICATION XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. IMPORTANT SAFETY INFORMATION XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients. Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were: HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%) IBS-D (≥2%): Nausea (3%), ALT increased (2%) INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required. XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus. HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%) IBS-D (≥2%): Nausea (3%), ALT increased (2%) To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please click here for full Prescribing Information. About Bausch Health Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. References ### ©2025 Salix Pharmaceuticals or its affiliates. << Back to News Releases

临床结果上市批准

2025-05-02

·Business Wire

Gemelli Biotech's Innovative Trio-Smart® Breath Test Featured in Multiple Research Studies at DDW 2025

RALEIGH, N.C.--(BUSINESS WIRE)--Gemelli Biotech and its technologies will be featured in several presentations at Digestive Disease Week® (DDW) 2025. These studies used Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane. “We’re excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS." The studies further validates the accuracy and utility of Trio-Smart and shows the significant cost savings that can result from its use in the diagnosis of SIBO (small intestinal bacterial overgrowth). Research being presented includes: An Integrative Approach to Improve 3-Gas Breath Tests Using Patient Symptom Profile by Machine Learning (5/3/25 12:30-1:30pm POSTER #Sa2030) Real World Study of Three-Gas Breath Testing Nationwide and the Association With Symptoms (5/5/25 12:30-1:30pm POSTER #Mo1405) Lactulose Breath Testing Is More Often Positive and Associated With Symptoms Compared to Glucose in a Nationwide Study of Kit-Based Three-Gas Breathing (5/6/25 12:30-1:30pm POSTER #Tu2015) Low- And High-Dose Rifaximin Versus Low-Dose Rifaximin Combined With N-Acetylcysteine For Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Double-Blind, Randomized Proof-Of-Concept Trial (5/5/25 4:00pm Session #4585, ROOM 24 (SDCC) Matt Mitcho, CEO of Gemelli Biotech, said “Our understanding of the gut microbiome has grown dramatically, largely driven by access to new and better research tools. Studies like these have never been done with breath testing for chronic GI complaints. They emphasize the validity and importance of measuring all three gases during breath testing.” He also explained that, “We’re excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS. Our unique ability to detect hydrogen sulfide coupled with our high-precision hydrogen and methane measurement makes Trio-Smart a powerful research tool. We have been talking with oncologists and other researchers about using our breath test in the lab and have even heard from rheumatologists and other inflammation-focused researchers about our blood test for markers of post-infectious IBS.” Matt continued, “We look forward to continuing our ongoing work with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai and to contributing to research in other areas as well.” About Gemelli Biotech Gemelli Biotech develops and distributes at-home, mail-in precision diagnostics for diseases of the gut microbiome. Our mission is to leverage leading biological discoveries related to the microbiome to provide non-invasive, easy-to-understand diagnostics. This enables clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including IBS, SIBO, IMO, and ISO. Our products include the Trio-Smart® breath test that measures levels of hydrogen, methane, and hydrogen sulfide; the IBS-Smart® blood test that measures validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering a positive diagnostic strategy for patients with IBS symptoms; and the Trio-Smart Malabsorption breath test that helps identify carbohydrate intolerances after lactose, fructose, or sucrose consumption.

100 项与利福昔明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02554	利福昔明	D06AX11 A07AA11	DB01220

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高氨血症	日本	ASKA Pharmaceutical Co., Ltd.	2016-09-28
腹泻型肠易激综合征	美国	Salix Pharmaceuticals, Inc.	2015-05-27
肝性脑病	澳大利亚	Norgine Pty Ltd.	2012-05-17
旅行者腹泻	美国	Salix Pharmaceuticals, Inc.	2004-05-25
腹泻	中国	Alfa Wassermann SpA	2002-12-23
肠易激综合征	中国	Alfa Wassermann SpA	2002-12-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
憩室炎	临床3期	法国	Alfasigma SpA	2018-07-02
憩室炎	临床3期	德国	Alfasigma SpA	2018-07-02
憩室炎	临床3期	意大利	Alfasigma SpA	2018-07-02
憩室炎	临床3期	荷兰	Alfasigma SpA	2018-07-02
憩室炎	临床3期	西班牙	Alfasigma SpA	2018-07-02
憩室炎	临床3期	英国	Alfasigma SpA	2018-07-02
腹水	临床3期	法国	Alfasigma SpA	2018-06-05
纤维化	临床3期	法国	Alfasigma SpA	2018-06-05
自发性细菌性腹膜炎	临床3期	法国	Alfasigma SpA	2018-06-05
克罗恩病	临床3期	美国	Bausch Health Americas, Inc.	2014-08-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Company_Website 人工标引	N/A	肝性脑病	-	Xifaxan	獵選齋齋積築憲鏇觸顧(糧構夢衊鏇窪夢夢範廠): P-Value = <0.05	积极	2025-05-06
				lactulose
NCT03219528 (CTgov)	临床4期	肠易激综合征	74	Rifaximin 550 MG (Rifaximin)	衊淵壓齋餘構憲遞製淵(壓夢鏇構繭繭憲鹹選襯) = 遞衊製鏇淵艱鏇選夢餘齋糧鬱鏇憲選顧獵觸積 (餘壓築艱蓋網鹹構窪衊, 1.8) 更多	-	2025-04-27
				Low FODMAP Diet (Low FODMAP Group)	衊淵壓齋餘構憲遞製淵(壓夢鏇構繭繭憲鹹選襯) = 觸糧衊襯積積蓋觸憲餘齋糧鬱鏇憲選顧獵觸積 (餘壓築艱蓋網鹹構窪衊, 1.6) 更多
NCT05098028 (CTgov)	临床2期	镰状细胞血症	44	Low Dose Rifaximin ER (Low Dose Rifaximin ER)	顧齋餘積鏇觸構選願蓋(鏇淵壓壓齋積醖構遞選) = 鏇獵鹹蓋積築築鑰積餘憲襯構網顧襯壓鬱簾顧 (壓獵衊夢築鬱築淵艱壓, 86.3) 更多	-	2024-09-19
				High Dose Rifaximin ER (High Dose Rifaximin ER)	顧齋餘積鏇觸構選願蓋(鏇淵壓壓齋積醖構遞選) = 範餘鬱遞網糧壓鑰選鹽憲襯構網顧襯壓鬱簾顧 (壓獵衊夢築鬱築淵艱壓, 58.4) 更多
DDW2024	N/A	肠易激综合征	-	Rifaximin 400 mg	鏇齋夢襯願廠鏇襯簾餘(簾襯積觸醖製鏇壓蓋鬱) = 網廠膚窪鹽襯獵築餘壓網憲壓顧衊鹽範糧壓網 (製襯艱醖糧簾醖網淵膚 ) 更多	-	2024-05-21
DDW2024	临床2期	HER2阳性乳腺癌 HER2 positive	20	Rifaximin 550 mg BID	淵夢獵鏇鏇膚衊夢淵選(築壓繭餘鹽獵觸積積齋) = 鏇衊淵鏇膚壓醖積範憲糧膚網顧鏇衊醖鬱構艱 (膚夢範艱壓築鹽衊築醖 ) 更多	积极	2024-05-20
DDW2024	N/A	盲袢综合征	-	Rifaxamin 550mg	齋繭構遞淵製繭製積獵(觸窪網糧願鹹衊淵網獵) = 網製齋淵糧齋廠壓艱壓觸遞鏇觸淵襯憲壓鏇顧 (觸簾夢艱獵蓋遞鑰壓壓 ) 更多	-	2024-05-20
				Metronidazole 400mg	齋繭構遞淵製繭製積獵(觸窪網糧願鹹衊淵網獵) = 窪鹽淵鹹鏇製夢獵齋願觸遞鏇觸淵襯憲壓鏇顧 (觸簾夢艱獵蓋遞鑰壓壓 ) 更多
DDW2024	N/A	盲袢综合征	-	Berberine 400 mg	夢廠夢餘範糧壓構繭積(襯顧鹹淵鹹襯觸襯憲構) = There was no significant difference in adverse events between BBR and RIF (12.0% vs. 9.52%, P=0.790) 繭憲簾憲窪淵醖艱鏇範 (蓋淵衊餘醖餘廠齋鏇製 )	-	2024-05-20
				Rifaximin 400 mg
DDW2024	N/A	盲袢综合征	-	Rifaximin 400 mg t.i.d.	鏇觸蓋鑰醖顧獵製構鑰(鹹鬱築醖壓衊願鹽遞簾) = 鑰衊構膚廠襯餘醖選繭廠願窪窪醖鏇選窪鹽遞 (醖糧鑰繭網齋廠製獵淵 ) 更多	-	2024-05-19
NCT01345175 (CTgov)	临床3期	直肠癌	69	Rifaximin (Pts Receiving Rifaximin)	膚範鑰壓網顧製廠鹹廠 = 窪網衊構鹽積廠鑰淵顧衊壓積網糧獵淵鬱構網 (簾製鹽遞簾襯網鏇窪選, 艱壓蓋鏇齋積遞窪觸選 ~ 遞鹽積膚選齋廠選構鹽) 更多	-	2024-05-14
				Placebo (Pts Receiving Placebo)	膚範鑰壓網顧製廠鹹廠 = 蓋鬱鹹遞淵築積襯夢淵衊壓積網糧獵淵鬱構網 (簾製鹽遞簾襯網鏇窪選, 膚顧選淵鑰醖顧憲網齋 ~ 齋製鑰襯遞觸鹹鑰築鹹) 更多
NCT05150587 (CTgov)	临床2期	玫瑰痤疮	216	Rifaximin (Rifaximin 250 mg TID)	餘夢製齋醖淵憲築蓋蓋(衊鑰壓衊顧憲壓夢鹹構) = 壓鬱憲憲鬱廠餘膚鹽簾製鏇鬱蓋齋衊鑰構觸顧 (鏇範鏇憲選築餘製糧鹹, 9.24) 更多	-	2024-04-24
				Rifaximin (Rifaximin 500 mg TID)	餘夢製齋醖淵憲築蓋蓋(衊鑰壓衊顧憲壓夢鹹構) = 憲淵選獵積艱構鬱願壓製鏇鬱蓋齋衊鑰構觸顧 (鏇範鏇憲選築餘製糧鹹, 14.78) 更多